000 01438 a2200397 4500
005 20250516185431.0
264 0 _c20140925
008 201409s 0 0 eng d
022 _a1932-6203
024 7 _a10.1371/journal.pone.0081302
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aFinkel, Richard S
245 0 0 _aPhase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy.
_h[electronic resource]
260 _bPloS one
_c2013
300 _ae81302 p.
_bdigital
500 _aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
650 0 4 _aChild
650 0 4 _aCodon, Nonsense
_xgenetics
650 0 4 _aDystrophin
_xmetabolism
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aMuscular Dystrophy, Duchenne
_xdrug therapy
650 0 4 _aOxadiazoles
_xtherapeutic use
700 1 _aFlanigan, Kevin M
700 1 _aWong, Brenda
700 1 _aBönnemann, Carsten
700 1 _aSampson, Jacinda
700 1 _aSweeney, H Lee
700 1 _aReha, Allen
700 1 _aNorthcutt, Valerie J
700 1 _aElfring, Gary
700 1 _aBarth, Jay
700 1 _aPeltz, Stuart W
773 0 _tPloS one
_gvol. 8
_gno. 12
_gp. e81302
856 4 0 _uhttps://doi.org/10.1371/journal.pone.0081302
_zAvailable from publisher's website
999 _c23377539
_d23377539